Jazz Pharmaceuticals Plc Unit Filed A Complaint In United States District Court For District Of Columbia; Complaint Seeking A Declaration That U.S. FDA Approval On May 1 Of NDA For Lumryz "Was Unlawful"
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals filed a complaint in the US District Court for the District of Columbia, seeking a declaration that the FDA's approval of the NDA for Lumryz on May 1 was unlawful.
June 22, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Jazz Pharmaceuticals is challenging the FDA's approval of Lumryz NDA, claiming it was unlawful.
Jazz Pharmaceuticals is directly involved in the legal complaint against the FDA. The outcome of this case may impact the company's operations and market position. However, the short-term impact on the stock price is uncertain as the legal process may take time.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100